Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

560 recalls, newest first

Class II · Moderate risk

Octreotide Acetate for Injectable Suspension

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Ongoing Sterility / contamination Teva Pharmaceuticals USA, Inc NDC 0480-9262-08 D-0406-2026
Class II · Moderate risk

Octreotide Acetate for Injectable Suspension

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Ongoing Sterility / contamination Teva Pharmaceuticals USA, Inc NDC 0480-9259-08 D-0405-2026
Class II · Moderate risk

Octreotide Acetate for Injectable Suspension

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Ongoing Sterility / contamination Teva Pharmaceuticals USA, Inc NDC 0480-9257-08 D-0404-2026
Class II · Moderate risk

Lanreotide Injection

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

Ongoing Sterility / contamination Cipla USA, Inc. NDC 69097-906-67 D-0423-2026
Class II · Moderate risk

Lanreotide Injection

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

Ongoing Sterility / contamination Cipla USA, Inc. D-0422-2026

Recalls by year